La Trobe

Glucose profiles of older adults with type 1 diabetes using sensor-augmented pump therapy in Australia: pre-randomisation results from the ORACL study

Download (651.13 kB)
journal contribution
posted on 2023-06-26, 06:24 authored by S Trawley, GM Ward, S Vogrin, PG Colman, S Fourlanos, CA Grills, MH Lee, RJ MacIsaac, AM Alipoor, DN O'Neal, NA O'Regan, Vijaya SundararajanVijaya Sundararajan, SA McAuley

Background: Older adults with type 1 diabetes are recommended modified glucose targets. However, data on the effects of diabetes technology in older age are scarce. We assessed older adults established on sensor-augmented insulin pump therapy during clinical trial run-in and compared their continuous glucose monitoring (CGM) profiles with consensus recommendations. We aimed to provide insight into the applicability of currently recommended CGM-based targets while accounting for current Diabetes UK guidelines. Methods: In this analysis, adults aged 60 years or older with type 1 diabetes with a duration of at least 10 years and entering the Older Adult Closed Loop (ORACL) trial were studied. The trial was done at two tertiary hospitals in Australia. Individuals who were independent with diabetes self-management, as well as those receiving caregiver assistance for their diabetes management, were eligible for inclusion. Participants underwent baseline clinical assessment, which included medical history and examination, testing for frailty, functional ability, cognitive functioning, psychosocial wellbeing, and subjective sleep quality; fasting venous blood samples were collected for C-peptide, glucose, and glycated haemoglobin A1c measurement. Sensor-augmented pumps, carbohydrate-counting education, and diabetes education were provided to participants by diabetes nurse educators, dietitians, and endocrinologists experienced in type 1 diabetes clinical care. CGM data were subsequently collected for 2 weeks during sensor-augmented pump therapy. The ORACL trial is registered with the Australian New Zealand Clinical Trial Registry, ACTRN12619000515190. Findings: Our analysis included all 30 participants who completed the ORACL trial run-in—19 (63%) women and 11 (37%) men (mean age 67 years [SD 5], median diabetes duration 38 years [IQR 20–47], and insulin total daily dose 0·55 units [0·41–0·66] per kg bodyweight). Ten (33%) of 30 participants had impaired hypoglycaemia awareness and six (20%) were pre-frail; none were frail. The median CGM time in range 3·9–10·0 mmol/L was 71% (IQR 64–79). The time spent with glucose above 10·0 mmol/L was 27% (18–35) and above 13·9 mmol/L was 3·9% (2·4–10·2). The time with glucose below 3·9 mmol/L was 2·0% (1·2–3·1) and the time below 3·0 mmol/L was 0·2% (0·1–0·4). Only two (7%) of 30 participants met all CGM-based consensus recommendations modified for older adults. Time in hypoglycaemia was lower among the 16 participants with predictive low-glucose alerts enabled than among the 14 participants not using predictive low-glucose alerts (median difference −1·1 percentage points [95% CI −2·0 to −0·1]; p=0·038). This difference was even greater overnight (−2·3 percentage points [−3·2 to −1·0]; p=0·0018). One serious adverse event occurred (elective cardiac stent). Interpretation: Using sensor-augmented pumps after multidisciplinary education, this group of older adults without frailty achieved a time in range far exceeding minimum consensus recommendations. However, the current stringent hypoglycaemia recommendations for all older adults were not met. Predictive low alerts could reduce hypoglycaemia, particularly overnight. Investigation into the effectiveness of CGM-based targets that consider frailty, functional status, and diabetes therapies for older adults is warranted. 

Funding

This work was funded by JDRF (3-SRA-2018-667-M-R), the Diabetes Australia Research Program, and St Vincent's Hospital (Melbourne) Research Endowment Fund. SAM is supported by a JDRF Research Award.

History

Publication Date

2022-12-01

Journal

The Lancet Healthy Longevity

Volume

3

Issue

12

Pagination

10p. (p. e839-e848)

Publisher

Elsevier

ISSN

2666-7568

Rights Statement

© 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license https://creativecommons.org/licenses/by/4.0/

Usage metrics

    Journal Articles

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC